Muscarinic antagonist control of myopia: Evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrew

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 9, 2012, Pages 5827-5837

  Arumugam, Baskar ^a   McBrien, Neville A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; MUSCARINIC TOXIN 3; MUSCARINIC TOXIN 7; PEPTIDE; SNAKE VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ECHOGRAPHY; HISTOLOGY; LENS; MONOCULAR DEPRIVATION; MYOPIA; NONHUMAN; PRIORITY JOURNAL; SCANDENTIA; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; SENSORY DEPRIVATION; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELAPID VENOMS; INTRAVITREAL INJECTIONS; MUSCARINIC ANTAGONISTS; MYOPIA; PEPTIDES; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; SENSORY DEPRIVATION; SIGNAL TRANSDUCTION; TUPAIIDAE;

EID: 84871682638     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9943     Document Type: Article

References (63)

1. Bedrossian RH. The effect of atropine on myopia. Ophthalmology. 1979;86:713-719.
2. Gimbel HV. The control of myopia with atropine. Can J Ophthalmol. 1973;8:527-532.
3. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113: 2285-2291.
4. Tigges M, Iuvone PM, Fernandes A, et al. Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys. Optom Vis Sci. 1999;76:397-407.
5. McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci. 1993;34:205-215.
6. Stone RA, Lin T, Laties AM. Muscarinic antagonist effects on experimental chick myopia. Exp Eye Res. 1991;52:755-758.
7. Cottriall CL, McBrien NA. The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew. Invest Ophthalmol Vis Sci. 1996;37:1368-1379.
8. Raviola E, Wiesel TN. An animal model of myopia. N Engl J Med. 1985;312:1609-1615.
9. Leech EM, Cottriall CL, McBrien NA. Pirenzepine prevents form deprivation myopia in a dose dependent manner. Ophthalmic Physiol Opt. 1995;15:351-356.
10. Cottriall CL, Truong HT, McBrien NA. Inhibition of myopia development in chicks using himbacine: a role for M4 receptors? Neuroreport. 2001;12:2453-2456.
11. Ostrin LA, Frishman LJ, Glasser A. Effects of pirenzepine on pupil size and accommodation in rhesus monkeys. Invest Ophthalmol Vis Sci. 2004;45:3620-3628.
12. Siatkowski RM, Cotter SA, Crockett RS, Miller JM, Novack GD, Zadnik K. Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study, of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS. 2008;12:332-339.
13. Bognar IT, Wesner MT, Fuder H. Muscarinic receptor types mediating autoinhibition of acetylcholine release and sphincter contraction in the guinea-pig iris. Naunyn Schmiedebergs Arch Pharmacol. 1990;341:22-29.
14. Choppin A, Eglen RM, Hegde SS. Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br J Pharmacol. 1998;124:883-888.
15. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther. 1991;256:727-733.
16. McBrien NA, Jobling AI, Truong HT, Cottriall CL, Gentle A. Expression of muscarinic receptor subtypes in tree shrew ocular tissues and their regulation during the development of myopia. Mol Vis. 2009;15:464-475.
17. Barathi VA, Weon SR, Beuerman RW. Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Molecular Vision. 2009;15:1277-1293.
18. Liu Q, Wu J, Wang X, Zeng J. Changes in muscarinic acetylcholine receptor expression in form deprivation myopia in guinea pigs. Mol Vis. 2007;13:1234-1244.
19. Qu J, Zhou X, Xie R, et al. The presence of m1 to m5 receptors in human sclera: evidence of the sclera as a potential site of action for muscarinic receptor antagonists. Curr Eye Res. 2006;31:587-597.
20. Yin GC, Gentle A, McBrien NA. Muscarinic antagonist control of myopia: A molecular search for the M1 receptor in chick. Mol Vis. 2004;10:787-793.
21. Tietje KM, Nathanson NM. Embryonic chick heart expresses multiple muscarinic acetylcholine receptor subtypes. Isolation and characterization of a gene encoding a novel m2 muscarinic acetylcholine receptor with high affinity for pirenzepine. J Biol Chem. 1991;266:17382-17387.
22. Luft WA, Ming Y, Stell WK. Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. Invest Ophthalmol Vis Sci. 2003;44:1330-1338.
23. Tan DT, Lam DS, Chua WH, Shu-Ping DF, Crockett RS. One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Ophthalmology. 2005;112:84-91.
24. Jolkkonen M, van Giersbergen PL, Hellman U, Wernstedt C, Karlsson E. A toxin from the green mamba Dendroaspis angusticeps: amino acid sequence and selectivity for muscarinic m4 receptors. FEBS Lett. 1994;352:91-94.
25. Servent D, Blanchet G, Mourier G, Marquer C, Marcon E, Fruchart-Gaillard C. Muscarinic toxins. Toxicon. 2011;58:455-463.
26. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009;8:41-54.
27. McBrien NA, Arumugam B, Gentle A, Chow A, Sahebjada S. The M4 muscarinic antagonist MT-3 inhibits form-deprivation myopia in chick: evidence for site of action. Ophthalmic Physiol Opt. 2011;31:529-539.
28. McBrien NA, Norton TT. Prevention of collagen crosslinking increases form-deprivation myopia in tree shrew. Exp Eye Res. 1994;59:475-486.
29. McBrien NA, Norton TT. The development of experimental myopia and ocular component dimensions in monocularly lidsutured tree shrews (Tupaia belangeri). Vision Res. 1992;32: 843-852.
30. McBrien NA, Gentle A. Role of the sclera in the development and pathological complications of myopia. Prog Retin Eye Res. 2003; 22:307-338.
31. McBrien NA, Cornell LM, Gentle A. Structural and ultrastructural changes to the sclera in a mammalian model of high myopia. Invest Ophthalmol Vis Sci. 2001;42:2179-2187.
32. Metlapally S, McBrien NA. The effect of positive lens defocus on ocular growth and emmetropization in the tree shrew. J Vis. 2008;8:1-12.
33. McBrien NA, Arumugam B, Metlapally S. The effect of daily transient +4 D positive lens wear on the inhibition of myopia in the tree shrew. Invest Ophthalmol Vis Sci. 2012;53:1593-1601.
34. Karlsson E, Jolkkonen M, Mulugeta E, Onali P, Adem A. Snake toxins with high selectivity for subtypes of muscarinic acetylcholine receptors. Biochimie. 2000;82:793-806.
35. Servent D, Fruchart-Gaillard C. Muscarinic toxins: tools for the study of the pharmacological and functional properties of muscarinic receptors. J Neurochem. 2009;109:1193-1202.
36. Norton TT, McBrien NA. Normal development of refractive state and ocular component dimensions in the tree shrew (Tupaia belangeri). Vision Res. 1992;32:833-842.
37. Siegwart JT, Norton TT. Goggle for controlling the visual environment of small animals. Lab Anim Sci. 1994;44:292-294.
38. McBrien NA, Lawlor P, Gentle A. Scleral remodeling during the development of and recovery from axial myopia in the tree shrew. Invest Ophthalmol Vis Sci. 2000;41:3713-3719.
39. Glickstein M, Millodot M. Retinoscopy and eye size. Science. 1970;168:605-606.
40. Tong L, Huang XL, Koh ALT, Zhang XE, Tan DTH, Chua WH. Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of Atropine. Ophthalmology. 2009;116:572-579.
41. Wildsoet C, Wallman J. Choroidal and scleral mechanisms of compensation for spectacle lenses in chicks. Vision Res. 1995; 35:1175-1194.
42. Siegwart JT, Norton TT. The susceptible period for deprivation induced myopia in tree shrew. Vision Res. 1998;38:3505-3515.
43. Schwahn HN, Kaymak H, Schaeffel F. Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. Vis Neurosci. 2000;17:165-176.
44. Diether S, Schaeffel F, Lambrou GN, Fritsch C, Trendelenburg AU. Effects of intravitreally and intraperitonally injected atropine on two types of experimental myopia in chicken. Exp Eye Res. 2007;84:266-274.
45. Doods HN, Entzeroth M, Ziegler H, Mayer N, Holzer P. Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle. Eur J Pharmacol. 1994;253:275-281.
46. Fischer AJ, Miethke P, Morgan IG, Stell WK. Cholinergic amacrine cells are not required for the progression and atropine-mediated suppression of form deprivation myopia. Brain Res. 1998;794: 48-60.
47. Vessey KA, Cottriall CL, McBrien NA. Muscarinic receptor protein expression in the ocular tissues of the chick during normal and myopic eye development. Brain Res Dev Brain Res. 2002;135:79-86.
48. Max SI, Liang JS, Potter LT. Stable allosteric binding of m1-toxin to m1 muscarinic receptors. Mol Pharmacol. 1993;44:1171-1175.
49. May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2007;47:1-51.
50. Tucek S, Musilkova J, Nedoma J, Proska J, Shelkovnikov S, Vorlicek J. Positive cooperativity in the binding of alcuronium and N-methylscopolamine to muscarinic acetylcholine receptors. Mol Pharmacol. 1990;38:674-680.
51. Ellis J, Huyler J, Brann MR. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol. 1991;42: 1927-1932.
52. Fischer AJ, Mcguire JJ, Schaeffel F, Stell WK. Light and focus dependent expression of the transcription factor ZENK in the chick retina. Nat Neurosci. 1999;2:706-712.
53. Bitzer M, Kovacs B, Feldkaemper M, Schaeffel F. Effects of muscarinic antagonists on ZENK expression in the chicken retina. Exp Eye Res. 2006;82:379-388.
54. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology. 2012;119:347-354.
55. Lind GJ, Chew SJ, Marzani D, Wallman J. Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes. Invest Ophthalmol Vis Sci. 1998;39:2217-2231.
56. Morgan IG, Van Rijswijk P, Megaw P. M4 muscarinic acetylcholine receptors mediate muscarinic of axial elongation in the chicken. Invest Ophthalmol Vis Sci. 2005;46:3342.
57. Cottriall CL, McBrien NA, Annies R, Leech EM. Prevention of form-deprivation myopia with pirenzepine: a study of drug delivery and distribution. Ophthalmic Physiol Opt. 1999;19: 327-335.
58. Field JR, Walker AG, Conn PJ. Targeting glutamate synapses in schizophrenia. Trends Mol Med. 2011;17:689-698.
59. Lebois EP, Bridges TM, Lewis LM, et al. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci. 2010;1:104-121.
60. Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2012;37:16-42.
61. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997; 54:465-473.
62. Shannon HE, Rasmussen K, Bymaster FP, et al. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42:249-259.
63. Barak S, Weiner I. The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801-and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol. 2011;14:1233-1246.